Brayboy Lynae M, Knapik Laura O, Long Sokunvichet, Westrick Mollie, Wessel Gary M
1Department of Obstetrics and Gynecology then Division of Reproductive Endocrinology and Infertility, Women & Infants Hospital of Rhode Island, 101 Dudley Street, Providence, RI 02905 USA.
2Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903 USA.
Contracept Reprod Med. 2018 Nov 15;3:26. doi: 10.1186/s40834-018-0076-7. eCollection 2018.
Multidrug resistance transporters (MDRs) are transmembrane proteins that efflux metabolites and xenobiotics. They are highly conserved in sequence and function in bacteria and eukaryotes and play important roles in cellular homeostasis, as well as in avoidance of antibiotics and cancer therapies. Recent evidence also documents a critical role in reproductive health and in protecting the ovary from environmental toxicant effects. The most well understood MDRs are MDR-1 (P-glycoprotein (P-gp) also known as ABCB1) and BCRP (breast cancer resistance protein) and are both expressed in the ovary. We have previously shown that MDR-1 mRNA steady state expression changes throughout the murine estrous cycle, but expression appears to increase in association with the surge in estradiol during proestrus.
Here we test the model that MDR-1 and BCRP are regulated by estrogen, the major hormonal product of the ovary. This was performed by administering 6-week-old female mice either sesame oil (vehicle control) or oral ethinyl estradiol at 1 μg, 10 μg, and 100 μg or PROGESTERONE at 0.25mg, 0.5 mg or 1 mg or a combination of both for 5 days. The mice were then sacrificed, and the ovaries were removed and cleaned. Ovaries were used for qPCR, immunoblotting, and immnunolabeling.
We found that oral ethinyl estradiol did not influence the steady state mRNA of MDR-1 or BCRP. Remarkably, the effect on mRNA levels neither increased or decreased in abundance upon estrogen exposures. Conversely, we observed less MDR-1 protein expression in the groups treated with 1 μg and 10 μg, but not 100 μg of ethinyl estradiol compared to controls. MDR-1 and BCRP are both expressed in pre-ovulatory follicles. When we tested progesterone, we found that MDR-1 mRNA increased at the dosages of 0.25 mg and 0.5 mg, but protein expression levels were not statistically significant. Combined oral ethinyl estradiol and progesterone significantly lowered both MDR-1 mRNA and protein.
Progesterone appears to influence MDR-1 transcript levels, or steady state levels. This could have implications for better understanding how MDR-1 can be modulated during times of toxic exposure. Understanding the normal physiology of MDR-1 in the ovary will expand the current knowledge in cancer biology and reproduction.
多药耐药转运蛋白(MDRs)是一种能将代谢物和外源性物质排出细胞的跨膜蛋白。它们在细菌和真核生物的序列和功能上高度保守,在细胞内稳态以及抗生素和癌症治疗的耐药性方面发挥重要作用。最近的证据还表明其在生殖健康以及保护卵巢免受环境毒物影响方面起着关键作用。人们对MDR-1(P-糖蛋白(P-gp),也称为ABCB1)和BCRP(乳腺癌耐药蛋白)这两种MDRs最为了解,它们都在卵巢中表达。我们之前已经表明,MDR-1 mRNA的稳态表达在小鼠发情周期中会发生变化,但在发情前期,其表达似乎会随着雌二醇的激增而增加。
在此,我们测试MDR-1和BCRP受卵巢主要激素产物雌激素调控的模型。通过给6周龄雌性小鼠分别注射芝麻油(溶剂对照)或口服1μg、10μg和100μg乙炔雌二醇,或0.25mg、0.5mg和1mg孕酮,或两者组合,持续5天。然后处死小鼠,取出并清理卵巢。卵巢用于定量PCR、免疫印迹和免疫标记。
我们发现口服乙炔雌二醇不会影响MDR-1或BCRP的稳态mRNA。值得注意的是,雌激素暴露后,mRNA水平既没有增加也没有减少。相反,与对照组相比,我们观察到在接受1μg和10μg但不是100μg乙炔雌二醇治疗的组中,MDR-1蛋白表达较少。MDR-1和BCRP都在排卵前卵泡中表达。当我们测试孕酮时,我们发现MDR-1 mRNA在0.25mg和0.5mg剂量时增加,但蛋白表达水平无统计学意义。联合口服乙炔雌二醇和孕酮显著降低了MDR-1的mRNA和蛋白水平。
孕酮似乎会影响MDR-1的转录水平或稳态水平。这可能有助于更好地理解在接触毒物期间如何调节MDR-1。了解卵巢中MDR-1 的正常生理功能将扩展当前癌症生物学和生殖领域的知识。